TP53 and colorectal carcinoma: We also found that MLN4924 significantly enhanced the expression of TRAIL-R2/DR5 in CRC cells, as well as Fas/CD95, both canonical p53 target genes (Fig. 3e and Supplementary Fig. 3A–C).